Dr. Cesar Rodriguez discussed treatment advancements for multiple myeloma during a CURE Educated Patient® Summit.

For higher-risk multiple myeloma (MM), successful patient selection and monitoring strategies are vital for the management of adverse events and the disease itself.

Why have BMS investors been anything but positive about acquiring 2seventy? The answer stems from uncertainty over how ...

Immunomodulatory drugs, such as lenalidomide (Revlimid), pomalidomide (Pomalyst), and thalidomide (Thalomid). They block the pathways that help multiple myeloma grow. People with refractory ...

DelveInsight's "CARVYKTI Market Size, Forecast, and Market Insight Report" highlights the details around CARVYKTI, a ...

The FDA has accepted the resubmitted BLA for linvoseltamab for patients with relapsed/refractory multiple myeloma.

While we've known that a healthy diet reduces the overall chance of getting cancer, there's now evidence that one eating plan ...

A panel of experts discussed the transition of care between community and academic centers at the CURE Educated Patient ...

DelveInsight's "DARZALEX Market Size, Forecast, and Market Insight Report" highlights the details around DARZALEX, a human ...

During a live event, Patrick Moore, MD, discussed the superior efficacy with ide-cel vs standard care in relapsed/refractory ...